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Abstract
Background: D-Cycloserine (DCS) enhances extinction learning across species, but it has proven challenging to
identify consistent benefit of DCS when added to therapeutic interventions. We conducted a placebo-controlled
trial of DCS to potentiate social skills training in autism spectrum disorder (ASD) but found substantial improvement
in both the DCS and placebo groups at the conclusion of active treatment. Here, we assess the impact of DCS
11 weeks following active treatment to evaluate the impact of DCS on treatment response durability.
Methods: Study participants included 60 outpatient youth with ASD, ages 5–11 years, all with IQ above 70, and
significantly impaired social functioning who completed a 10-week active treatment phase during which they
received weekly single doses of 50 mg of DCS or placebo administered 30 min prior to group social skills training.
Following the 10-week active treatment phase, blinded follow-up assessments occurred at week 11 and week 22.
The primary outcome measure for our durability of treatment evaluation was the parent-rated social responsiveness
scale (SRS) total raw score at week 22.
Results: Analysis of the SRS total raw score demonstrated significant decrease for the DCS group compared to the
placebo group (p = 0.042) indicating greater maintenance of treatment effect in the DCS group. DCS was well
tolerated, with irritability being the most frequently reported adverse effect in both groups.
Conclusions: The findings of this study suggest that DCS may help youth with ASD to maintain skills gained
during sort-term social skills training. Larger-scale studies with longer follow-up will be necessary to further
understand the long-term impact of DCS paired with structured social skills training.
Trial registration: ClinicalTrials.gov, NCT01086475
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Background
Social impairment is a defining feature and key predictor
of long-term outcome in autism spectrum disorder
(ASD) [1, 2]. Social skills training explicitly targets this
core deficit and is widely implemented in ASD treatment
[2]. Adolescent social skills groups consistently demon-
strate immediate improvements in social and communi-
cation skills in participants during treatment; however,
participants tend to show limited sustained treatment
response over longer term follow-up [2–4].
One possible way to improve long-term outcomes of
social skills training would be to potentiate the effect of
the intervention with adjunctive pharmacotherapy.
Recent studies have shown that D-cycloserine (DCS), a
partial agonist at the glycine site of the N-methyl-D-as-
partate (NMDA) receptor, may potentiate response to
behavioral therapy [5–9]. DCS appears to potentiate ex-
tinction learning, with most significant benefit from
intermittent dosing immediately prior to behavioral con-
ditioning in animals or psychotherapy session in humans
[10]. The ability of DCS to augment learning appears to
be related to NMDA receptor-dependent neural
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plasticity within the basolateral amygdala [8]. Multiple
studies have suggested a role of the glutamate system in
the pathophysiology of ASD [11], including rare, disrup-
tive mutations in an NMDA receptor subunit gene [12].
In mouse models of ASD, glutamatergic modulators
have been associated with improvement in sociability
[12–14], but human studies have been less promising
[15–17]. DCS studies in ASD have been primarily short-
term monotherapeutic interventions which have not
demonstrated consistent, convincing improvements in
core features of ASD [18–20]. To date, no studies in
ASD have evaluated the combined impact of DCS and
therapeutic interventions.
With these facts in mind, our group designed a ran-
domized, double-blind, placebo-controlled trial of low-
dose DCS given 30 min prior to weekly peer-mediated
group social skills training in youth with ASD. As
described by Minshawi et al., at the conclusion of active
treatment (week 11), participants in the DCS and
placebo groups both demonstrated notable improvement
in social functioning, but there was no statistically sig-
nificant difference between the groups on primary or
secondary outcome measures at the end of treatment
(primary outcome measure social responsiveness scale
(SRS) change score t test p value = 0.45) [21]. In the
current manuscript, we review results from the post-
treatment observation phase of the study (week 11
through week 22), during which participants had no fur-
ther medication or study interventions, but returned for
assessment at week 22 with the goal of measuring poten-
tial sustained treatment effects of DCS plus social skills
training.
Methods
Trial design and participants
This study evaluated blinded week 22 durability of treat-
ment data collected following a 10-week randomized,
double-blind, placebo-controlled DCS plus peer-mediated
social skills group intervention in high functioning youth
with ASD completed between August 4, 2009 and January
23, 2014 at Indiana University School of Medicine (IUSM)
and Cincinnati Children’s Hospital Medical Center
(CCHMC). Please see manuscript by Minshawi et al. for
full details describing study design, participants, and stat-
istical analysis of the data collected during and immedi-
ately following the 10-week intervention [21]. Both the
10-week intervention and week 22 treatment durability
analysis were approved by the institutional review board
(IRB) at each participating site (Indiana University
Institutional Review Board and Cincinnati Children’s
Hospital Medical Center Institutional Review Board).
Guardians of all participants provided written informed
consent prior to study enrollment. Assent was obtained
from enrolled youth when possible.
Study participants were youth ages 5–11 years re-
cruited from outpatient psychiatric clinics at both sites
and via IRB approved advertising. Participants were
diagnosed with autistic disorder, Asperger’s disorder, or
pervasive developmental disorder, not otherwise speci-
fied (PDD-NOS) by clinical assessment based on the
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition Text revision (DSM-IV-TR) diagnostic
criteria [22], and corroborated by administration of the
Autism Diagnostic Observation Schedule (ADOS) [23]
and the Autism Diagnostic Interview-Revised (ADI-R)
[24]. Due to the cognitive and verbal demands of the so-
cial skills intervention, subjects were required to have an
Intellectual Quotient (IQ) above 70 as measured by the
Stanford-Binet Fifth Edition (SB-V) [25] and a Vineland
Adaptive Behavior Scale Second Edition (VABS-II) [26]
communication standard score above 70. At baseline, all
subjects demonstrated significant social impairment with
T-scores of 60 or greater on the SRS [27] and scores of
70% or less on both the parent questionnaire and child
assessment portions of the Triad Social Skills
Assessment (TSSA) [28].
Concurrent psychotropic medication use was permit-
ted, though all subjects were required to remain on
stable doses throughout the treatment intervention and
through week 22 durability of treatment effect analysis.
Participants were excluded if treated with more than
two psychotropic medications or known glutamatergic
modulators such as riluzole, memantine, acamprosate,
topiramate, or amantadine among others. Participants
enrolled in psychosocial interventions independent from
the study protocol were required to have stable regimens
throughout the study. Participants were excluded from
the study if they were participating in concurrent group
social skills training programs.
For the 10-week intervention phase of the study, par-
ticipants were enrolled in a series of 17 social skills
groups (13 at IUSM and 4 at CCHMC), each containing
four children with ASD and two typically developing,
age-matched peer models. Peer models were determined
to be free of psychiatric symptoms or developmental dis-
ability via the Child Symptom Inventory-4 [29] and a
medical and psychiatric interview completed by a study
physician. Subjects with ASD were randomized to either
DCS or placebo in a 1:1 ratio by computer-generated
randomization list accessible only by the investigational
pharmacist. A dose of 50 mg DCS or placebo was ad-
ministered 30 min prior to 10 weekly, 2-h sessions of
manualized social skills training. Social skills interven-
tion followed a curriculum utilizing ABA-based
techniques designed to teach skills including greetings,
understanding emotions, creative play, and social con-
versations [30]. Social skills groups were divided by age
(5–7 years or 8–11 years), and minor modifications were
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made to the group curriculum to accommodate the dif-
ferent age ranges. Groups were instructed by masters or
doctorate level clinicians with specific expertise and
experience working with youth with ASD.
Following the 10-week intervention phase, participants
received no ongoing study-related therapeutic interven-
tion or treatment with study drug. Participants were
asked to return at week 11 and week 22 for blinded
assessment. Participants, caregivers, and investigators
remained blind to study group-assignment until after all
week 22 follow-up visits were completed, all data was
recorded in a RedCap database, quality checks were
completed, and the data set was locked.
Finally, we incorporated a pilot eye-tracking paradigm
of gaze preference employing a Tobii T120 Infrared Eye
Tracker integrated with a 17-inch thin film transistor
monitor controlled with Tobii Studio software (Version
3.0). Eye-tracking assessment was completed at week 11
and week 22 in a subset of participants beginning in year
3 of the project. In this pilot assessment, participants
viewed 60 colored photographs of adult human faces
from the NimStim Face Stimuli Set [31] and percent
time looking at the eye, nose, mouth, or whole face
region was calculated (Fig. 1). Time spent viewing the
eye region and face as a whole implied greater social
interest in comparison to time spent looking at other
facial regions [32–34].
Outcome assessments and statistical analysis
Demographic data were collected at screen, prior to
randomization to study group. Monitoring for adverse
events was completed by a study physician at all visits
via discussion of new symptoms, recent doctor visits,
and current medication review. The primary outcome
measure at week 22 (and at week 11) was the parent-
rated SRS total raw score. Exploratory outcome mea-
sures at week 22 were the SRS subscale component
scores. The SRS total raw score ranges from 0 to 195,
with higher scores indicating more significant social
impairment [27].
Demographic data describing the week 22 completers in
the DCS and placebo groups (age, gender, ASD subtype,
and concomitant medications), as well as reported adverse
events/frequencies were compared using Student’s t tests
for continuous variables and Fisher’s exact tests for
categorical variables. Wilcoxon rank sum tests were
completed to validate results of the Student’s t tests.
To assess potential impact of participants lost to
follow-up, we compared using Wilcoxon rank sum tests
the week 22 completers versus those who dropped out
before week 11 on the SRS total raw score at baseline.
We also compared these completers to those who
dropped out before week 22 on the change in SRS total
raw score from baseline to week 11.
To examine the differences between the groups on
SRS total raw scores from week 11 to week 22, we
employed a robust linear model based on M-estimation,
specifically the bisquare weight function (or biweight),
which is the default method in the SAS ® statistical soft-
ware package (SAS ® version 9.3, SAS Institute Inc.,
Cary, NC). A robust linear model was used because pre-
liminary analyses indicated that the data contained some
outliers. Rather than omitting these points (i.e., setting
their weight to zero) and fitting parameters using least
squares, we preferred to downweight the outliers based
on their distance from the bulk of the data. The biweight
Fig. 1 Face image from the NimStim Face Stimuli Set with highlighted areas of interest. The individual pictured in this figure was not a study participant
Wink et al. Molecular Autism  (2017) 8:2 Page 3 of 8
was used because it provides smoothly changing weights
to all of the observations, including the outliers [35]. In
our model, the response was the SRS total raw score at
week 22 and the independent variable was treatment
group (DCS or placebo). The weightings account for the
SRS total raw score at week 11 as well as the covariates
gender, age group (5–7 versus 8–11 years), and ASD
diagnosis (autistic disorder versus Asperger’s disorder
and PDD-NOS combined). Since this model is predict-
ing week 22 SRS total raw scores while controlling for
week 11 SRS total raw scores with the weightings, this
model predicts relative change in this measure from
week 11 to week 22. The weighted estimates are similar
to means, but are more resistant to the adverse effects of
outliers, and refer to the effect plus the value of the
biweight estimator at week 22. The biweight estimator is
a weighted average of the week 22 results; adding this
value to the treatment effects allows the estimates to be
comparable to raw values.
The effect sizes resulting from the robust linear model
described above were calculated by dividing the magni-
tude of treatment effect by the robust measure of scale
produced by the model above. In the spirit of Cohen’s d,
which is based on means and the standard deviation, we
will refer to this effect size as dbiw, to indicate that this
effect size is based on robust biweight estimators. Simi-
lar versions of the effect size based on different robust
models have been discussed by Wilcox and Tian [36].
To correct for multiple exploratory post hoc compari-
sons, false discovery rate (FDR) procedures were utilized
for the secondary SRS subscale analyses.
For the pilot eye-tracking data, a repeated measures
linear mixed model was conducted where the response
was the percent fixation time at a particular area of
interest (SAS ® version 9.3). The continuous covariate
was the baseline percent fixation time and the categor-
ical independent variables were treatment group and
week 11 or week 22 as well as their interaction term.
The “week” term was the repeated measure within sub-
jects (which is the random effect). Other covariates
included the face identifier, expression, mouth (open or
closed), age group, gender, and ASD subtype. The least
squares means were derived for each treatment by week
combination. The contrast comparing the treatment
change between the two weeks of interest was then
derived.
Results
Review of week 11 findings [21]
In brief, the 10-week intervention phase of the study, de-
scribed in detail by Minshawi et al., enrolled 68 children
with ASD with no statistically significant treatment
group differences in demographics, clinical factors, con-
comitant medications, therapeutic interventions, or SRS
total raw score at baseline [21]. Mean SRS total raw
score decreased during the intervention phase in both
groups. At week 11, the SRS change scores from baseline
demonstrated no statistically significant difference attrib-
utable to DCS treatment. DCS was well tolerated, with
irritability being the most frequently reported adverse
effect in both groups. There was no statistically signifi-
cant difference in number of reported adverse events
between groups. A supplementary figure providing a
comprehensive overview of the mean SRS total raw
scores across all study phases, including both the initial
study treatment phase (week 11 endpoint) and the long-
term follow-up (week 22 endpoint) was included as a
supplementary file for reference (please see Additional
File 1).
Week 22 findings
Sixty participants completed week 22 (four subjects were
lost during active treatment phase and four lost during
follow-up period, consort diagram, Fig. 2). At week 22,
there were no statistically significant differences between
treatment groups in age, gender, diagnostic subtype, or
concomitant medications (Table 1). In our examination
of the impact of participants lost to follow-up, we found
no statistically significant difference between the week
22 completers and those who were lost to follow-up
prior to week 11 on the SRS total raw score at baseline
(Wilcoxon Rank Sum p value = 0.90). Furthermore, we
found no statistically significant difference when we
compared these completers to those who dropped
out before week 22 on the change in SRS total raw
score from baseline to week 11 (Wilcoxon rank sum
p value = 0.91).
The robust linear model employed in this analysis to
examine the difference between DCS and placebo groups
on SRS total raw scores from week 11 to week 22 demon-
strates that the DCS group decreased significantly com-
pared to the placebo group (DCS mean estimate = 85.1
(SE 7.3), placebo mean estimate = 91.5 (SE 7.6), DCS-pla-
cebo estimate (treatment effect) = −6.4 (SE 3.1), p = 0.042,
dbiw = 0.69). This suggests that DCS increased durability
of social skills training gains at week 22 in those children
treated with active drug. These differences account for
week 11 SRS scores as well as gender, age, and diagnosis
because of the robust linear model used in analysis. Effect
size is in the moderate to large range, indicating that the
observed change was meaningful [37]. The size of the ef-
fect is apparent in that the treatment effect (the difference
between the DCS estimated mean and the placebo esti-
mated mean) is only slightly smaller than the SEs of each
of the estimated means.
In the secondary analysis of the SRS subscales, the so-
cial cognition subscale showed the greatest between
groups difference (p = 0.003, dbiw = 0.82). When we
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corrected for multiple exploratory comparisons utilizing
FDR procedures, this effect remained significant. There
were no statistically significant differences between
groups on the social awareness, social communication,
social motivation, and autistic mannerism subscales.
Finally, the pilot eye-tracking measure was completed
in 38 subjects, 21 in the DCS group and 17 in the pla-
cebo group. There was no statistically significant differ-
ence identified between these groups in age, sex,
diagnostic subtype, or concomitant medications. Results
demonstrated that the DCS treatment group had
decreased percent time looking at the nose, but
increased percent time looking at the face as a whole
(p < 0.0001) when compared to the placebo group.
There was no difference in percent time spent view-
ing the eye or mouth regions between groups. As the
social skills curriculum employed in this study dir-
ectly taught and reinforced eye gaze to the face and
eyes region, this data suggests that the DCS treated
group was potentially more successful at gaining this
skill and was therefore more socially interested in
viewing faces in the eye-tracking paradigm at week 22
as a result of receiving active drug.
Discussion
To our knowledge, this study combing social skills
therapeutic intervention with medication is the first of
its kind to be completed in ASD research. The week 11
results reported by Minshawi et al. demonstrating de-
creased SRS total scores in both treatment groups but
Fig. 2 Consort diagram







Age (years), mean (SDa) 8.47 (1.83) 8.07 (1.53) 0.37
Sex, n (%) male 26 (81.35) 23 (82.14) 1.00
Diagnosis, n (%) autistic disorder 12 (37.50) 12 (52.86) 0.79
Concomitant medications, n (%)
Antipsychotics 6 (18.75) 4 (14.29) 0.74
Alpha-2 agonists 6 (18.75) 6 (21.43) 1.00
Stimulants 11 (34.38) 7 (25.00) 0.57
Antidepressants 3 (9.38) 3 (10.72) 1.00
Atomoxetine 1 (3.13) 1 (3.57) 1.00
Any concomitant medication 19 (59.39) 17 (60.71) 1.00
Mean total concomitant medications 0.84 0.75 0.64
SD standard deviation
aDCS D-Cycloserine
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not between group treatment effects align with previous
reports of substantial immediate impact of social skills
training in youth with ASD [2]. In this follow-up study,
we show enhanced durability of treatment response in
those subjects who received weekly DCS, a novel finding
considering previous studies indicating lack of treatment
durability following social skills intervention in ASD [4].
In this analysis, DCS appears to support maintenance of
social skills gains made during short-term group therapy
compared to placebo. This improved maintenance of ef-
fect was measured both by parent-reported increased
social cognition and by our pilot eye-tracking paradigm.
Furthermore, this medication’s long track record of safe
use in children, limited adverse effects in this study, and
demonstrated impact with intermittent dosing in other
disorders suggests significant potential for future treat-
ment development of DCS in ASD.
There are several limitations of our trial design that
must be considered when interpreting the results of this
study. First, we utilized a novel, peer-mediated manua-
lized social skills training curriculum for this study [30].
Although the curriculum is based on validated ABA-
based techniques, the curriculum itself has not been val-
idated outside of this study. Second, the social skills
training design limited this intervention to a selective
group of children with relatively high communication
and adaptive functioning, limiting the inferences that
can be made regarding intermittent DCS dosing to sup-
port learning in youth with ASD more generally. Third,
the SRS was designed as an assessment tool rather than
as an outcome measure, the subscales were derived via
expert consensus and may not reflect a true underlying
construct, and the large range of potential scores present
a challenge in interpreting the exact meaning of a score
change [27, 38]. However, we made the choice to employ
this measure as our primary outcome as this measure
was most in line with the core social impairments we
hoped to address via our study intervention, and has also
been used in other social skills training studies in youth
with ASD [39]. Fourth, our eye-tracking paradigm was
piloted only in a subgroup of participants in this study,
limiting the impact of these results. Future studies could
continue to explore the use of eye tracking as a potential
objective measure of social interest by including all study
participants in the trial design. Last, the specific mecha-
nisms underlying the longer term benefits of DCS, such
as reduction of social anxiety during treatment or im-
provements in learning and memory during therapy, re-
main to be established. Despite these limitations, the
prospect of enhancing the sustained benefit of social skill
training interventions with pharmacotherapy is novel
and exciting. Given that social skills training is a primary
intervention for ASD but one with limited long-term
benefits, the added impact of DCS could significantly
improve the long-term social functioning of children
with ASD. Replication of the observed effects would re-
quire a larger study that is explicitly focused on sus-
tained benefit. Additional work is also needed to
determine the mechanisms underlying the benefit of
DCS added to social skills training.
Conclusions
Adjunctive DCS significantly increased the sustained
benefit from short-term social skills intervention
3 months after treatment cessation. This is of import-
ance considering the body of literature suggesting lim-
ited durability of therapeutic interventions targeting core
features of ASD. Additionally, the safety and time lim-
ited nature of this drug treatment, as demonstrated by
the limited adverse effects reported by study partici-
pants, indicates that DCS may be a safe and effective
strategy to enhance the durability of therapy impact in
youth with ASD. This finding holds significant potential
in ASD where there are no approved treatments for the
core social skills deficits associated with the disorder.
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